...1...25.....37...37......73.....86..........92... 98. 106...110...110...115...121...129...137...145......150...159...159...163...170...179...187...200
.....203.....203........208.....212.........215........224........229....235....235....238
1-1-P.1
1-1-P.2
1-1-P.3
1-1-P.4
From ADAClinical Practice Recommendations 2003 1-1-P.5
1-1-P.6
1-1-P.7
1-1-P.8
1. 2. 3. 4. 5. 6. 7. 8. 1-1-P.9
9. 10. 11. 12. 13. 14. 15. 1-1-P.10
16. 17. 18. 19. 20. 21. 22. 1-1-P.11
23. 24. 25. 26. 1-1-P.12
1-2-P.13
1-2-P.14
1-2-P.15
1-2-P.16
1-2-P.17
1-2-P.18
1-2-P.19
1-2-P.20
1-2-P.21
1-2-P.22
1-2-P.23
1-2-P.24
2- -P.25
2- -P.26
2- -P.27
2- -P.28
2- -P.29
2- -P.30
2- -P.31
2- -P.32
2- -P.33
µ 2- -P.34
2- -P.35
2- -P.36
3-1-P.37
3-1-P.38
3-1-P.39
3-1-P.40
3-1-P.41
3-1-P.42
3-1-P.43
3-1-P.44
3-1-P.45
3-1-P.46
3-1-P.47
3-1-P.48
3-1-P.49
3-1-P.50
1. 2. 3. 3-1-P.51
4. 5. 6. 7. 8. 9. 3-1-P.52
3-2-P.53
3-2-P.54
3-2-P.55
3-2-P.56
3-2-P.57
3-2-P.58
3-2-P.59
3-2-P.60
3-2-P.61
3-2-P.62
3-2-P.63
3-2-P.64
3-2-P.65
3-2-P.66
3-2-P.67
3-2-P.68
3-2-P.69
3-2-P.70
3-2-P.71
3-2-P.72
3-3-P.73
3-3-P.74
3-3-P.75
3-3-P.76
3-3-P.77
3-3-P.78
3-4-P.79
3-4-P.80
3-4-P.81
3-4-P.82
3-4-P.83
8. 3-4-P.84
3-4-P.85
4-1-P.86
β 4-1-P.87
4-1-P.88
4-1-P.89
4-1-P.90
4-1-P.91
β β % % % % % % 4-2-P92
4-2-P93
4-2-P94
4-2-P95
4-2-P96
4-2-P97
4-3-P98
4-3-P99
4-3-P100
4-3-P101
4-3-P102
4-3-P103
4-3-P104
4-3-P105
µ µ µ µ 5- -P106
5- -P107
5- -P108
5- -P109
6-1 -P110
6-1 -P111
6-1 -P112
6-1 -P113
6-1 -P114
6-2 -P115
6-2 -P116
6-2 -P117
6-2 -P118
6-2 -P119
6-2 -P120
6-3-P.121
6-3-P.122
6-3-P.123
6-3-P.124
6-3-P.125
6-3-P.126
6-3-P.127
6-3-P.128
6-4-P129
µ µ 6-4-P130
β α α β α 6-4-P131
6-4-P132
6-4-P133
6-4-P134
6-4-P135
6-4-P136
6-5-P137
6-5-P138
β γ 6-5-P139
6-5-P140
κ κ α α 6-5-P141
6-5-P142
ω 6-5-P143
6-5-P144
6-6-P145
6-6-P146
6-6-P147
6-6-P148
6-6-P149
6 7 P.150
6 7 P.151
6 7 P.152
6 7 P.153
6 7 P.154
2.Rvdel-Seiffer 64Hz 0-8 5 (Liniger et al.) 4 ( ) (ankle:brachial index, ABI, A/B ratio) 50%ABI 0.95-1.25 1.31 0.89 Doppler ABI(Coleman Birke) 6 7 P.155
(Total contact cast) 6 7 P.156
6 7 P.157
6 7 P.158
7 2 P.159
7 2 P.160
β 7 2 P.161
β β β 7 2 P.162
7 2 P.163
7 2 P.164
7 2 P.165
7 2 P.166
7 2 P.167
7 2 P.168
7 2 P.169
7-3-P170
7-3-P171
7-3-P172
7-3-P173
7-3-P174
7-3-P175
7-3-P176
7-3-P177
7-3-P178
7-4-P179
7-4-P180
7-4-P181
7-4-P182
7-4-P183
7-4-P184
7-4-P185
7-4-P186
7-5-P 187
7-5-P 188
7-5-P 189
(3) (Intensive therapy) 3 ( ) 4 70 120 / <180 / 65 / (4) (Premeal Regular and Bedtime Intermediate-Acting Insulin) 7-2 30 7-2 (5) 7-5-P 190
7-3 7-4 7-5-P 191
7-5 (CSII) 7-5-P 192
7-5-P 193
7-5-P 194
7-5-P 195
7-5-P 196
7-5-P 197
7-5-P 198
7-5-P 199
7-6-P 200
X 2-3 2-3 (GKI) 2-3 7-6-P 201
7-6-P 202
8-1-P 203
8-1-P 204
8-1-P 205
8-1-P 206
8-1-P 207
8-2-P.208
8-2-P.209
8-2-P.210
8-2-P.211
8-3-P. 212
8-3-P. 213
8-3-P. 214
8-4-P. 215
8-4-P. 216
217 8-4-P.
8-4-P. 218
8-4-P. 219
8-4-P. 220
8-4-P. 221
8-4-P. 222
8-4-P. 223
8-5-P. 224
8-5-P. 225
8-5-P. 226
8-5-P. 227
228 8-5-P.
9 P 229
9 P 230
9 P 231
9 P 232
233 9 P
234 9 P
10- P-235
10- P-236
10- P-237
10- P-238
10- P-239
10- P-240
10- P-241